GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Benitec Biopharma Inc (NAS:BNTC) » Definitions » Beneish M-Score

Benitec Biopharma (Benitec Biopharma) Beneish M-Score : -4.14 (As of Apr. 29, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Benitec Biopharma Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -4.14 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Benitec Biopharma's Beneish M-Score or its related term are showing as below:

BNTC' s Beneish M-Score Range Over the Past 10 Years
Min: -11.8   Med: -1.64   Max: 256.23
Current: -4.14

During the past 11 years, the highest Beneish M-Score of Benitec Biopharma was 256.23. The lowest was -11.80. And the median was -1.64.


Benitec Biopharma Beneish M-Score Historical Data

The historical data trend for Benitec Biopharma's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Benitec Biopharma Beneish M-Score Chart

Benitec Biopharma Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -0.92 -7.28 11.53

Benitec Biopharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.15 7.35 11.53 11.61 -4.14

Competitive Comparison of Benitec Biopharma's Beneish M-Score

For the Biotechnology subindustry, Benitec Biopharma's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Benitec Biopharma's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Benitec Biopharma's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Benitec Biopharma's Beneish M-Score falls into.



Benitec Biopharma Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Benitec Biopharma for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.7922+0.528 * 0.3141+0.404 * 0.4191+0.892 * 0.9839+0.115 * 0.7589
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9099+4.679 * -0.171077-0.327 * 1.1268
=-4.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $0.05 Mil.
Revenue was 0 + 0 + 0.007 + 0.054 = $0.06 Mil.
Gross Profit was -0.001 + 0.106 + 0.007 + 0.054 = $0.17 Mil.
Total Current Assets was $20.80 Mil.
Total Assets was $21.35 Mil.
Property, Plant and Equipment(Net PPE) was $0.45 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.34 Mil.
Selling, General, & Admin. Expense(SGA) was $5.97 Mil.
Total Current Liabilities was $5.75 Mil.
Long-Term Debt & Capital Lease Obligation was $0.14 Mil.
Net Income was -6.798 + -5.954 + -4.661 + -4.397 = $-21.81 Mil.
Non Operating Income was 0.135 + -0.074 + -0.103 + -0.049 = $-0.09 Mil.
Cash Flow from Operations was -5.365 + -4.577 + -4.095 + -4.029 = $-18.07 Mil.
Total Receivables was $0.07 Mil.
Revenue was 0.014 + 0 + 0 + 0.048 = $0.06 Mil.
Gross Profit was 0.014 + 0 + -0.009 + 0.048 = $0.05 Mil.
Total Current Assets was $10.98 Mil.
Total Assets was $11.91 Mil.
Property, Plant and Equipment(Net PPE) was $0.79 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.38 Mil.
Selling, General, & Admin. Expense(SGA) was $6.67 Mil.
Total Current Liabilities was $2.49 Mil.
Long-Term Debt & Capital Lease Obligation was $0.42 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.053 / 0.061) / (0.068 / 0.062)
=0.868852 / 1.096774
=0.7922

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(0.053 / 0.062) / (0.166 / 0.061)
=0.854839 / 2.721311
=0.3141

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (20.796 + 0.451) / 21.353) / (1 - (10.975 + 0.789) / 11.905)
=0.004964 / 0.011844
=0.4191

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=0.061 / 0.062
=0.9839

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.381 / (0.381 + 0.789)) / (0.339 / (0.339 + 0.451))
=0.325641 / 0.429114
=0.7589

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(5.974 / 0.061) / (6.673 / 0.062)
=97.934426 / 107.629032
=0.9099

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0.137 + 5.746) / 21.353) / ((0.422 + 2.489) / 11.905)
=0.275512 / 0.244519
=1.1268

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-21.81 - -0.091 - -18.066) / 21.353
=-0.171077

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Benitec Biopharma has a M-score of -4.14 suggests that the company is unlikely to be a manipulator.


Benitec Biopharma Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Benitec Biopharma's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Benitec Biopharma (Benitec Biopharma) Business Description

Traded in Other Exchanges
N/A
Address
3940 Trust Way, Hayward, CA, USA, 94545
Benitec Biopharma Inc is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The company is developing product candidates in chronic and life-threatening human disease areas including Orphan disease: Oculopharyngeal Muscular Dystrophy (OPMD) and Infectious disease: Hepatitis B Virus (HBV). BB-301 is currently under development by the group; it is designed to slow, or halt, the disease progression.
Executives
J Kevin Buchi director 41 MOORES ROAD, FRAZER PA 19355
Megan Boston director, officer: Executive Director LEVEL 14, 114 WILLIAM ST, MELBOURNE, VIC C3 3000
Steven Michael Oliveira 10 percent owner 18 FIELDSTONE COURT, NEW CITY NY 10956
Patrick Soon-shiong 10 percent owner 9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
Edward F Smith director C/O POLYMEDIX, INC., 3701 MARKET STREET, PHILADELPHIA PA 19104
California Capital Equity, Llc 10 percent owner 10182 CULVER BOULEVARD, CULVER CITY CA 90232
Nant Capital, Llc 10 percent owner 9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
Peter Francis director LEVEL 14, 114 WILLIAM ST, MELBOURNE, VIC C3 3000
Jerel A. Banks director, officer: Chief Executive Officer LEVEL 14, 114 WILLIAM ST, MELBOURNE, VIC C3 3000